Keith Regnante - CHIEF FINANCIAL OFFICER at Keros Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Financial Officer
Stock Symbol
KROS on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

Keith Regnante - trading volume in the past year for Keros Therapeutics, Inc.

Holdings reported by Keith Regnante for Keros Therapeutics, Inc.

Class Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Employee Stock Option (right to buy) 40K Feb 13, 2024 Direct Common Stock
Common Stock 0 $45.29 Nov 4, 2023 Direct

Transactions reported by Keith Regnante for Keros Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.